DexCom, Inc. Financials

Market Capitalization $32.77 Billion as of July 1, 2025

Valuations Metrics as of Jul. 4, 2025

Trailing PE	62.84
Forward PE	41.17
Price to Sales TTM	$7.90
Price to Book MRQ	$14.46
Enterprise to Revenue	8.22
Enterprise to EBITDA	39.76

Financial Reports as of Mar. 31, 2025

Financials

Fiscal Year Ends	2024-12-31
Most Recent Quarter	2025-03-31
Profit Margin	12.90%
Operating Margin	12.91%
Return on Assets TTM	5.98%
Return on Equity TTM	23.72%

Income Statement

Revenue TTM	$4,148,000,000
Revenue per Share TTM	$10.53
Quarterly Revenue Growth	12.50%
Gross Profit TTM	$2,465,299,968
EBITDA	$975,100,000
Net Income to Common TTM	$535,200,000
Diluted EPS TTM	$1.33
Quarterly Earnings Growth YoY	-28.00%

Balance Sheet

Total Cash MRQ	$2,701,400,064
Total Cash per Share MRQ	$6.89
Total Debt MRQ	$
Total Debt to Equity MRQ	113.97
Current Ratio MRQ	1.50
Book Value per Share MRQ	$5.78

Cash Flow

Operating Cash Flow TTM	$964,099,968
Levered Free Cash Flow TTM	$509,037,504

DXCM Stock Info as of Jul. 4, 2025

Stock Statistics

Shares Outstanding	390,700,000
Float Shares	389,378,433
Avg 10 Volume	4,855,470
Avg 30 Volume	None
Shares Short	9,375,485
Short Ratio	3.29
Short % of Shares	3.06%
% Held by Insiders	0.42%
% Held by Institutions	97.10%

Stock Price Summary

Beta	1.46
Fifty Two Week Low	$57.52
Fifty Two Week High	$117.19
Fifty Two Week Change	-37.09%
Day 50 MA	$82.15
Day 200 MA	$77.44

Dividends and Splits

Forward Annual Dividend Rate	$
Forward Annual Dividend Yield	%
Trailing Annual Dividend Rate	$0.00
Trailing Annual Dividend Yield	0.00%
Payout Ratio	0.00%
Dividend Date
Ex Dividend Date
Last Split Factor
Last Split Date	2022-06-13